AARON CIECHANOVER, MD, PhD
Nobel Prize Laureate, Professor of Biochemistry, Technion Institute of Technology
Professor Ciechanover is a recipient of the 2004 Nobel Prize in Chemistry for, in collaboration with colleagues at the Massachusetts Institute of Technology, identifying the first ubiquitin system mutant cell and demonstrating the role of the ubiquitin-proteasome proteolytic system in protein degradation in vivo. Professor Ciechanover obtained his MD from the Hadassah-Hebrew University Medical School in Jerusalem, and his PhD from the Faculty of Medicine at the Technion Israel Institute of Technology in Haifa. He is the winner of the 2000 Albert Lasker award for basic medical research and the 2001 Israel Prize in Biological Research. Professor Ciechanover's present work aims to elucidate the mode of recognition of specific target substrates and the role of the system in the degradation of nuclear oncoproteins and in activation and elimination of transcription factors.


ALIZA ESHKOL, PhD
Advisor for Scientific Affairs, Serono International SA, Geneva, Switzerland
Dr. Eshkol joined Serono in 1984 as Chief Scientist, and later became the company’s VP for Scientific Affairs. She played a major role in the company’s transition from its traditional extractive products to biotechnology. Dr. Eshkol was instrumental in setting up Serono’s critical R&D structures, including all functions required for obtaining marketing authorizations, from preclinical development through clinical trial and regulatory management. Prior to joining Serono, she worked from 1960 at the Institute of Endocrinology, Sheba Medical Center, Tel Hashomer, Israel. At Tel Hashomer her research activity was focused on the regulation of gonadal development and function, including purification of protein hormones, setting up of animal models and development of analytical and biological assay methods for both basic and clinical research. There she was involved in the development of diagnostic and therapeutic approaches for infertility treatment and monitoring. The elucidation by Dr. Eshkol of the function and interplay of certain hormones led to the development by Serono of new generations of hormonal products. At Serono, Dr. Eshkol continues to evaluate research projects, and assess the validity of their scientific merits and the potential for their transformation into medically valid products. She is a member of multiple national and international professional societies and NGOs. Dr. Eshkol earned her PhD in Life Sciences from Bar-Ilan University, in Ramat Gan, Israel.

DAVID LADKANI, PhD
Chief Scientific Officer, Global Products Division, Teva Pharmaceutical Industries
A seasoned drug developer, Dr. Ladkani received his PhD from the Hebrew University in Jerusalem. After serving as a Project Manager at the Dead Sea Works, he joined Teva Pharmaceuticals in 1979 as the Director of Bone Disease R&D. He served as a Senior Director of Scientific and Medical Affairs for the Copaxone Division, and now leads the scientific activities of the Global Products Division. He has received the prestigious Rothschild Award for innovation, and is widely published in the field of Multiple Sclerosis treatments.


MOSHE PHILLIP, MD
Vice President of Medical Affairs and Senior Clinical Advisor, BioLineRx
Professor Phillip is the Director of the Institute for Endocrinology and Diabetes, Israel National Center for Childhood Diabetes and served as the Vice Dean and Head of School for Continuing Medical Education of the Sackler School of Medical Education at Tel Aviv University. Professor Phillip manages the Institute’s Clinical Research Center (CRC), with in house research coordinators, statisticians, nurses and physicians. Professor Phillip is the senior PI of numerous clinical studies including Growth hormone (norditropin), Lantus (Sanofi Aventis), Detemir (Novo Nordisk), Candersartan Cilexetil (Astra Zeneca), and Medtronic’s patented insulin pump and glucose sensors. Professor Phillip's expertise and experience in both bench and clinical research includes clinical studies from Phase II to post marketing. His bench research is focused mainly on finding ways to prevent diabetic complications and understanding the interaction between hormones and the epiphyseal growth plate, while his clinical research focuses on diabetes and growth, including studies in immunomodulation and prevention of diabetes mellitus. Professor Phillip is an Associate Editor and on the editorial board of 3 medical journals and a member of the Pediatric and Diabetic National Councils of Health.

YAAKOV NAPARSTEK, MD
Chairman of Medicine, Hadassah University Hospital
Dr. Naparstek is a graduate of the Hadassah-Hebrew University Medical School in Jerusalem.
He is board certified in Internal Medicine, Rheumatology, Clinical Immunology and Allergy. Dr. Naparstek has been a research fellow and a visiting professor at the Weizmann Institute of Science, Tuft's University, The National Institute of Health, and Stanford University. Dr. Naparstek is currently a Professor of Medicine in the Hebrew University in Jerusalem. He is the Chairman of Medicine in the Hadassah University Hospital, as well as the Director of the Hadassah Clinical Immunology and Rheumatology Center. Dr. Naparstek is the incumbent of the Leifferman Chair in Rheumatology. His main research interests are in the field of autoimmunity, SLE and autoimmune arthritis. Dr. Naparstek is the recipient of national and international awards, the author of over 100 publications and chapters in textbooks and holds a number of patents in the field of autoimmune inflammatory diseases.

ITAMAR SHALIT, MD
Director, Pediatric Infectious Disease Unit, Schneider Children's Medical Center
Dr. Shalit obtained his MD from Tel Aviv University Sackler School of Medicine, completed a fellowship in Pediatric Infectious Diseases at the University of Oklahoma and an MPA Degree at Harvard University. Dr. Shalit brings to BioLineRx years of experience in research and clinical trials including collaborations with international pharmaceutical companies such as Bayer AG, Smith-Klein-Beecham, Eli Lilly, Glaxo Group Research and Miles Pharmaceuticals. Dr. Shalit has a broad background in R&D both in his former capacity in R&D positions in the IDF Medical Corps, and as a researcher and consultant to various companies, VCs and incubators. His main areas of research include the study of immunomodulatory effects of quinolones, the study of anti-inflammatory and signal transduction mechanisms and study of novel anti-fungal agents and their combinations. Dr. Shalit is a long-standing member of several Israel Ministry of Health committees focusing on designing the national vaccination program, preparedness against bio-terrorism and eradication of poliomyelitis. Dr. Shalit received a Certificate of Appreciation from the World Health Organization (WHO) for his contribution and outstanding efforts and success in poliomyelitis eradication in Israel. Dr. Shalit is the author of over 70 publications in leading scientific journals and chapters in textbooks and currently serves as the Chairman of the Israeli Society for Infectious Diseases.

YOSEF YARDEN, PhD
Dean of the Feinberg Graduate School, Weizmann Institute of Science
Dr. Yarden brings to BioLineRx over twenty years in the life-science field. Dr. Yarden has served as the Director of the M.D. Moross Institute for Cancer Research, the Vice President for Academic Affairs at the Weizmann Institute of Science and the Dean, Faculty of Biology at the Weizmann Institute of Science where he is also a Professor in the Department of Biological Regulation. He serves on numerous national and international boards and the scientific advisory committees of several organizations, both academic and commercial, including serving as a Council Member of the European Association for Cancer Research. Dr. Yarden has received several awards and honors including the John F. Kennedy Prize for excellence in Ph.D. studies, the Chaim Weizmann Fellowship for postdoctoral research, the Andre Lwoff Prize from the Pasteur Institute and Hoechst-Behring, as well as an invited member of the American Association for Cancer Research and elected member of the Asia-Pacific International Molecular Biology Network. He received his BSc. in geology and biology from the Hebrew University in Jerusalem and his Ph.D in Immunology from the Weizmann Institute in Rehovot. He completed postdoctoral research in molecular biology at Genentech Inc. in San Francisco and in oncogenesis at the Whitehead Institute in Cambridge.